Haywood analyst Neal Gilmer maintained a Buy rating on Trulieve Cannabis today and set a price target of C$15.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Neal Gilmer has given his Buy rating due to a combination of factors that highlight Trulieve Cannabis’s strong financial performance and strategic positioning. The company’s EBITDA margins have consistently outperformed expectations, with the latest quarter showing adjusted EBITDA of $102.7 million, surpassing both Gilmer’s and consensus estimates. This indicates effective cost management and operational efficiency, contributing to a robust financial outlook.
Additionally, Trulieve’s retail operations demonstrate resilience and growth potential, with retail revenue making up a significant portion of total revenue. The company has seen an increase in total traffic and product sales, alongside impressive customer retention rates. With a substantial number of retail locations and strategic expansions, Trulieve is well-positioned to capitalize on market opportunities, justifying the Buy rating.